Catalyst Pharmaceuticals, INC Form 4 insider transactions

A Catalyst Pharmaceuticals executive, Steve Miller, exercised stock options and sold shares on the open market, according to a recent SEC filing.

Director Tamar Thompson acquired 1,413 shares of Catalyst Pharmaceuticals common stock through the vesting of restricted stock units.

Gary Ingenito, Chief Medical and Regulatory Officer at Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.

Director David S. Tierney acquired 1,413 shares of Catalyst Pharmaceuticals common stock through the vesting of restricted stock units.

Brian Elsbernd, Chief Compliance/Legal Officer at Catalyst Pharmaceuticals, reported the vesting of restricted stock units and subsequent tax withholding.

Patrick J. McEnany, a director at Catalyst Pharmaceuticals, acquired 3,533 shares of common stock through the vesting of restricted stock units.

Director Molly Harper of Catalyst Pharmaceuticals acquired 1,413 shares of common stock through the vesting of restricted stock units.

Director Charles B. O'Keeffe of Catalyst Pharmaceuticals acquired shares and options through the vesting of restricted stock units and the exercise of options.

Director Donald A. Denkhaus acquired 1,413 shares of Catalyst Pharmaceuticals common stock through the vesting of restricted stock units.

Preethi Sundaram, Chief Strategy Officer at Catalyst Pharmaceuticals, exercised stock options and sold shares to cover taxes on December 9, 2024.

Jeffrey Del Carmen, Chief Commercial Officer at Catalyst Pharmaceuticals, reports the vesting and subsequent sale of shares to cover taxes.

A Catalyst Pharmaceuticals executive, Gary Ingenito, exercised stock options and sold a portion of the acquired shares on the open market.

Director Molly Harper of Catalyst Pharmaceuticals exercised stock options and sold the resulting shares on November 27, 2024.

Brian Elsbernd, Chief Compliance/Legal Officer at Catalyst Pharmaceuticals, exercised stock options and sold a portion of the acquired shares for tax purposes.

Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, acquired 137,553 stock options and 16,809 restricted stock units on November 21, 2024.

Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, acquired stock options and restricted stock units, increasing her beneficial ownership in the company.

Patrick McEnany, a director at Catalyst Pharmaceuticals, acquired options and restricted stock units, increasing his holdings in the company.

Catalyst Pharmaceuticals' Chief Operating and Scientific Officer, Steve Miller, was granted stock options and restricted stock units on November 21, 2024.

Catalyst Pharmaceuticals director Donald A. Denkhaus acquired options and restricted stock units on November 21, 2024, increasing his holdings in the company.

Director David S. Tierney of Catalyst Pharmaceuticals acquired options and restricted stock units on November 21, 2024, increasing his holdings in the company.

Gary Ingenito, Chief Medical and Regulatory Officer at Catalyst Pharmaceuticals, acquired stock options and restricted stock units on November 21, 2024.

Catalyst Pharmaceuticals' Executive Vice President & CFO, Michael Wayne Kalb, acquired 169,248 stock options and 20,682 restricted stock units on November 21, 2024.

Director Charles B. O'Keeffe of Catalyst Pharmaceuticals acquired stock options and restricted stock units on November 21, 2024, increasing his holdings in the company.

Catalyst Pharmaceuticals CEO Richard Daly was granted stock options and restricted stock units, increasing his beneficial ownership in the company.

Director Molly Harper of Catalyst Pharmaceuticals acquired stock options and restricted stock units, increasing her beneficial ownership in the company.

Catalyst Pharmaceuticals' Chief Compliance/Legal Officer, Brian Elsbernd, has acquired stock options and restricted stock units, increasing his beneficial ownership in the company.

Director Tamar Thompson acquired shares and options in Catalyst Pharmaceuticals, according to a recent SEC filing.

Gary Ingenito, Chief Medical and Regulatory Officer at Catalyst Pharmaceuticals, sold 38,000 shares after exercising options at a lower price.

Patrick J. McEnany, Chairman of Catalyst Pharmaceuticals, sold a portion of his shares after exercising stock options, while remaining the largest individual shareholder.

Patrick J. McEnany, Chairman of Catalyst Pharmaceuticals, sold a portion of his holdings after exercising stock options, while remaining the largest individual shareholder.